Each year, more than six million Americans are affected by acute infectious conjunctivitis, better known as pinkeye. It is uncomfortable, highly contagious, and costly for families, schools, and employers. Patrick Smale, co-founder and CEO of ClearSight Therapeutics, is determined to change that reality. His team is developing the first and only over-the-counter (OTC) treatment that specifically targets viral pinkeye, addressing a gap that has long frustrated patients and providers.
From Industry Insight to Innovation
Patrick’s career in eye care has included leadership and marketing roles at Alcon Labs. That experience gives him a clear perspective on a critical problem: most pinkeye cases are viral, not bacterial. Yet the majority of available treatments are antibacterial, leaving patients with ineffective solutions and prolonged symptoms.
Recognizing this mismatch, Patrick and his team built ClearSight with a patient-first mission: to provide a safe, effective, and easily accessible OTC remedy for viral conjunctivitis. Their vision is straightforward and groundbreaking: deliver relief directly to the people who need it most, without unnecessary prescriptions or wasted time.
The Strategic Pivot That Changed the Game
Like many startups, ClearSight initially pursued a traditional pharmaceutical pathway. But as strong safety data emerged, the company made a bold pivot to focus on consumer health. This decision was transformative. By moving into the OTC space, ClearSight shortened its timeline to market, reduced capital requirements, and opened doors to consumer-focused health accelerators.
The pivot also reflects a growing trend across healthcare startups: leveraging nontraditional pathways to scale faster while keeping patient accessibility at the core. For ClearSight, this approach means millions of families may soon have an affordable treatment available at their local pharmacy.
Accelerating Growth with MassChallenge
Innovation doesn’t happen in isolation, and ClearSight’s journey underscores the power of community. Through MassChallenge, Patrick and his team gained access to world-class mentors, a supportive peer network, and valuable connections across the biotech ecosystem.
This collaborative environment helped the company refine its go-to-market strategy, strengthen its funding mix, and secure critical visibility in one of the world’s most competitive healthcare hubs. For Patrick, MassChallenge proved to be more than an accelerator; it was a launchpad.
Standing Out in a Crowded Market
Healthcare innovation often struggles to balance safety, affordability, and speed to market. ClearSight is proving that all three are possible. By delivering an OTC viral pinkeye treatment, the company is:
- Reducing unnecessary prescriptions for antibiotics that are ineffective against viral cases.
- Providing relief for families faster, minimizing missed school and workdays.
- Empowering consumers with a safe, effective option that doesn’t require navigating complex healthcare systems.
With a strong financial outlook and a clear differentiation strategy, ClearSight plans to expand its impact and continue driving patient-centered innovation in eye care.
Looking Ahead
ClearSight Therapeutics represents the kind of bold, mission-driven innovation that defines the MassChallenge community. By addressing a widespread health challenge with a practical, patient-first solution, Patrick Smale and his team are reshaping what accessible healthcare looks like.